MX378999B - Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). - Google Patents
Fosforamidita de agrupacion de n-acetilgalactosamina (galnac).Info
- Publication number
- MX378999B MX378999B MX2018005733A MX2018005733A MX378999B MX 378999 B MX378999 B MX 378999B MX 2018005733 A MX2018005733 A MX 2018005733A MX 2018005733 A MX2018005733 A MX 2018005733A MX 378999 B MX378999 B MX 378999B
- Authority
- MX
- Mexico
- Prior art keywords
- phosphoramidite
- galnac
- acetylgalactosamine
- clustering
- sup
- Prior art date
Links
- 150000008300 phosphoramidites Chemical class 0.000 title abstract 3
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 title 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/08—Polyoxyalkylene derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención comprende derivados de fosforamidita de GalNAc de fórmula I (ver Fórmula) en donde R1 es un grupo protector de hidroxi, n es un número entero de 0 a 10 y m es un entero de 0 a 20 y sus enantiómeros correspondientes y/o isómeros ópticos de los mismos. La invención comprende además un proceso para la preparación de los derivados de fosforamidita de GalNAc de fórmula I y su uso en la preparación de conjugados de agrupación de GalNAc -oligonucleótidos terapéuticamente valiosos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194811 | 2015-11-16 | ||
| PCT/EP2016/077516 WO2017084987A1 (en) | 2015-11-16 | 2016-11-14 | GalNAc CLUSTER PHOSPHORAMIDITE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005733A MX2018005733A (es) | 2018-08-09 |
| MX378999B true MX378999B (es) | 2025-03-10 |
Family
ID=54695483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005733A MX378999B (es) | 2015-11-16 | 2016-11-14 | Fosforamidita de agrupacion de n-acetilgalactosamina (galnac). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10590156B2 (es) |
| EP (1) | EP3377510B1 (es) |
| JP (1) | JP6649482B2 (es) |
| KR (1) | KR102117172B1 (es) |
| CN (1) | CN108738321B (es) |
| AR (1) | AR106683A1 (es) |
| AU (1) | AU2016357980B2 (es) |
| BR (1) | BR112018003910B1 (es) |
| CA (1) | CA2994787A1 (es) |
| ES (1) | ES2848122T3 (es) |
| IL (1) | IL258149B (es) |
| MX (1) | MX378999B (es) |
| PL (1) | PL3377510T3 (es) |
| WO (1) | WO2017084987A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3013683C (en) | 2016-03-14 | 2021-07-13 | F. Hoffmann-La Roche Ag | Oligonucleotides for reduction of pd-l1 expression |
| JP7048574B2 (ja) | 2017-03-10 | 2022-04-05 | 国立研究開発法人国立成育医療研究センター | アンチセンスオリゴヌクレオチドおよび糖原病Ia型予防または治療用組成物 |
| WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE |
| SG11202002149XA (en) * | 2017-09-14 | 2020-04-29 | Janssen Biopharma Inc | Galnac derivatives |
| WO2019172286A1 (ja) | 2018-03-09 | 2019-09-12 | 第一三共株式会社 | 糖原病Ia型治療薬 |
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| CA3134494A1 (en) * | 2019-05-20 | 2020-11-26 | Simon Adolf BREITLER | Process for the preparation of galnac phosphoramidite epimers |
| IL291251B2 (en) | 2019-09-10 | 2026-06-01 | Daiichi Sankyo Co Limited | CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF |
| CN110668933B (zh) * | 2019-09-30 | 2024-09-24 | 兰州交通大学 | 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸(apea-7)的方法 |
| CN110759824B (zh) * | 2019-09-30 | 2024-09-24 | 兰州交通大学 | 一种合成烯丙基脂肪醇聚氧乙烯醚羧酸(apea-3)的方法 |
| US12534435B2 (en) | 2020-03-27 | 2026-01-27 | Generation Bio Co. | Lipids and nanoparticle compositions thereof |
| CN117642380A (zh) | 2021-06-14 | 2024-03-01 | 世代生物公司 | 阳离子脂质及其组合物 |
| EP4471140A1 (en) * | 2022-01-30 | 2024-12-04 | Rona Bioscience, Limited | Targeting ligand containing n-acetylgalactosamine |
| IL315659A (en) | 2022-03-16 | 2024-11-01 | Daiichi Sankyo Co Ltd | siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2 |
| EP4495241A1 (en) | 2022-03-16 | 2025-01-22 | Daiichi Sankyo Company, Limited | Chemically-modified oligonucleotide having rnai activity |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4420730A3 (en) | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| RU2013117288A (ru) * | 2010-12-17 | 2015-01-27 | Эрроухэд Рисерч Корпорейшн | СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА |
| PL2992098T3 (pl) * | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| MX367083B (es) * | 2013-06-27 | 2019-08-05 | Roche Innovation Ct Copenhagen As | Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9). |
| KR20160083876A (ko) | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| WO2015168589A2 (en) * | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
-
2016
- 2016-11-14 WO PCT/EP2016/077516 patent/WO2017084987A1/en not_active Ceased
- 2016-11-14 AR ARP160103468A patent/AR106683A1/es active IP Right Grant
- 2016-11-14 BR BR112018003910-1A patent/BR112018003910B1/pt active IP Right Grant
- 2016-11-14 CN CN201680065443.6A patent/CN108738321B/zh active Active
- 2016-11-14 EP EP16797831.1A patent/EP3377510B1/en active Active
- 2016-11-14 AU AU2016357980A patent/AU2016357980B2/en active Active
- 2016-11-14 CA CA2994787A patent/CA2994787A1/en active Pending
- 2016-11-14 PL PL16797831T patent/PL3377510T3/pl unknown
- 2016-11-14 JP JP2018523484A patent/JP6649482B2/ja active Active
- 2016-11-14 KR KR1020187008037A patent/KR102117172B1/ko active Active
- 2016-11-14 ES ES16797831T patent/ES2848122T3/es active Active
- 2016-11-14 MX MX2018005733A patent/MX378999B/es unknown
-
2018
- 2018-03-15 IL IL258149A patent/IL258149B/en active IP Right Grant
- 2018-05-14 US US15/978,815 patent/US10590156B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018532764A (ja) | 2018-11-08 |
| EP3377510B1 (en) | 2020-12-02 |
| ES2848122T3 (es) | 2021-08-05 |
| US10590156B2 (en) | 2020-03-17 |
| BR112018003910A2 (pt) | 2018-09-25 |
| KR102117172B1 (ko) | 2020-06-01 |
| AU2016357980A1 (en) | 2018-02-22 |
| MX2018005733A (es) | 2018-08-09 |
| IL258149B (en) | 2020-06-30 |
| BR112018003910B1 (pt) | 2022-03-22 |
| CA2994787A1 (en) | 2017-05-26 |
| AU2016357980B2 (en) | 2020-06-25 |
| CN108738321B (zh) | 2021-06-11 |
| WO2017084987A1 (en) | 2017-05-26 |
| IL258149A (en) | 2018-05-31 |
| EP3377510A1 (en) | 2018-09-26 |
| CN108738321A9 (zh) | 2021-01-29 |
| US20180258122A1 (en) | 2018-09-13 |
| AR106683A1 (es) | 2018-02-07 |
| CN108738321A (zh) | 2018-11-02 |
| PL3377510T3 (pl) | 2021-05-04 |
| KR20180041225A (ko) | 2018-04-23 |
| JP6649482B2 (ja) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106683A1 (es) | FOSFORAMIDITA DE AGRUPACIÓN DE GalNAc | |
| MX380122B (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| MA46325A (fr) | Composés dinucléotidiques cycliques | |
| BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
| MX2017015662A (es) | Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac). | |
| MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| BR112016006151A2 (pt) | imidazopiridazinas úteis como inibidores da via de sinalização do par-2 | |
| CO6511283A2 (es) | Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer | |
| BR112018009252A2 (en) | osteoarthritis treatment | |
| MX389367B (es) | Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2. | |
| UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
| MX2021008094A (es) | Metodos y composiciones para el tratamiento del cancer. | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| MX2017003238A (es) | Metodo para preparar 2'-o-fucosil-lactosa. | |
| BR112023012947A2 (pt) | Inibidores de lrrk2 | |
| CO2022009260A2 (es) | Composiciones farmacéuticas oftálmicas | |
| MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
| MX2022006320A (es) | Composicion para la inhibicion de la produccion de hmf que comprende disacarido de alulosa. | |
| BR112015015229A8 (pt) | processo para a preparação de um composto da fórmula, e, composto | |
| BR112019000290A2 (pt) | pró-fármacos de fósforo dos estimuladores da scg | |
| MX2022006003A (es) | Glucolipidos y composiciones farmaceuticas de los mismos para usarse en terapia. | |
| MX392144B (es) | Compuestos tipo pederina y el uso de los mismos en el tratatamiento de cáncer. | |
| MX2021014111A (es) | Proceso para la preparacion de epimeros de fosforamidita de galnac. | |
| MX2020012065A (es) | Compuestos de ciclopentano. |